Compare Globus Medical Inc. Class A Common Stock (GMED) vs Raytheon Technologies Corp (RTX) Price & Performance

Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.

GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.

RTX trades at $186.66, up 0.37% on the day, with a bearish technical signal but strong fundamental momentum. The company reported revenue of $88.60 billion in 2025, with net income of $6.73 billion and a profit margin of 7.59%. Recent earnings beats and a $289 billion backlog highlight robust demand in aerospace and defense. Analyst consensus is bullish with a $233.55 price target, though technical indicators show near-term resistance.

The outlook for RTX is positive, driven by sustained defense spending and commercial aviation recovery. Investment opportunities include earnings growth and dividend yield, while risks involve execution on the large backlog and potential defense budget fluctuations. The stock offers value if it can maintain its growth trajectory amid geopolitical tailwinds.